Table 2.
CART administration, toxicity, and efficacy.
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | |
|---|---|---|---|---|---|
| CAR+ cells infused (×106) | 150 | 450 | 800 | 800 | 450 |
| Adverse events of interest | |||||
| CRS grade | None | 2 | 1 | 2 | 3 |
| CRS duration (days) | 0 | 2 | 0 | 1 | 2 |
| Hematologic adverse events | |||||
| Neutropenia (grade) | Yes (1) | Yes (4) | Yes (4) | Yes (3) | Yes (4) * |
| Anemia (grade) | No | Yes (2) | Yes (2) | Yes (3) | Yes (3) |
| Thrombocytopenia (grade) | No | Yes (4) | Yes (3) | Yes (4) | Yes (4) * |
| Duration of Hematologic toxicity ** (days) | 4 | 90 | 144 | 125 | NA |
| Febrile Neutropenia | No | Yes | Yes | No | Yes |
| Efficacy | |||||
| Best hematologic response | CR | CR | CR | CR | CR |
| MRD negativity Day 30 Day 180 |
Yes Yes |
Yes No |
Yes Yes |
Yes Yes |
Yes No |
| Time to best confirmed response (days) | 30 | 30 | 60 | 30 | 30 |
| DOR (months) | 10 | 6 | 17 | 17 Ongoing |
4 |
Abbreviations: CR: complete remission; CRS: cytokine release syndrome; DOR: duration of response; MRD: minimal residual disease; * Started with grade 4 due to MDS. ** Duration to resolution to grade 2 or better.